ArticleJournal of clinical hypertension (Greenwich, Conn.)2019
Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03381950 (Chronic Kidney Disease - Renal Epidemiology and Information Network), which is not on this map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Chronic Kidney Disease - Renal Epidemiology and Information Network: The CKD-REIN Cohort
Who cites it
39 citing papers in PubMed, 63 citations in OpenAlex.
- Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF.Circulation. Heart failure · 2024Trial
- Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex.Journal of general internal medicine · 2024Trial
- Patiromer-Facilitated Renin-Angiotensin-Aldosterone System Inhibitor Utilization in Patients with Heart Failure with or without Comorbid Chronic Kidney Disease: Subgroup Analysis of DIAMOND Randomized Trial.American journal of nephrology · 2024Trial
- Impact of renin-angiotensin system inhibitors discontinuation in advanced chronic kidney disease: a target trial emulation.Clinical kidney journal · 2026Article
- Hyperkalemia Management in the US Cohort of the Prospective, Observational, Real-World TRACK Study.Advances in therapy · 2026Article
- Relationship between medication class and ambulatory blood pressure profile in the chronic renal insufficiency cohort (CRIC) study.Journal of human hypertension · 2026Article
- Prevalence of Hyperkalemia in a Contemporary European Cohort According to EKFC eGFR Categories.Diagnostics (Basel, Switzerland) · 2026Article
- Long-term patiromer adherence and renin-angiotensin aldosterone system inhibitor utilization: A retrospective study.World journal of nephrology · 2026Article
- Article
- Review of Hyperkalemia Profile for Mineralocorticoid Receptor Antagonist in Patients with Chronic Kidney Disease and Type 2 Diabetes.Cardiorenal medicine · 2026Review
- Quality indicators and clinical outcomes: the role of care quality in nondiabetic chronic kidney disease management.Renal failure · 2025Article
- Implementation of Guideline-Directed medical therapy and factors in heart failure with reduced ejection fraction.BMC cardiovascular disorders · 2025Article
- Optimization of renin-angiotensin-aldosterone inhibitor therapies for evidence-based indications: A call to action from the cardio-kidney community.American journal of preventive cardiology · 2025Article
- Optimization of renin-angiotensin-aldosterone inhibitor therapies for evidence-based indications: a call to action from the cardio-kidney community.ESC heart failure · 2025Article
- Optimization of Renin-Angiotensin-Aldosterone Inhibitor Therapies for Evidence-Based Indications: a Call to Action From the Cardio-Kidney Community.Kidney international reports · 2025Article
- In the Era of Cardiovascular-Kidney-Metabolic Syndrome in Cardio-Oncology: From Pathogenesis to Prevention and Therapy.Cancers · 2025Review
- Potassium management and heart failure: a nephrologist's perspective.Clinical kidney journal · 2025Article
- Chronic kidney disease in older adults: challenges and opportunities for the primary care provider.BMC primary care · 2024Review
- Clinical Outcomes in Patients with CKD and Rapid or Non-rapid eGFR Decline: A Report from the DISCOVER CKD Retrospective Cohort.Advances in therapy · 2024Article
- Renin-angiotensin system inhibitors prescriptions in Chinese hospitalized chronic kidney disease patients.World journal of clinical cases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 10 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renin-angiotensin-aldosterone system inhibitors (RAASi) are recommended for chronic kidney disease (CKD) patients. In this study, we describe RAASi prescription patterns in the Chronic Kidney Disease Outcomes and Practice Patterns Study (CKDopps) in Brazil, Germany, France, and the United States (US). 5870 patients (mean age 66-72 years; congestive heart failure [CHF] in 11%-19%; diabetes in 43%-54%; serum potassium ≥5 in 20%-35%) were included. RAASi prescription was more common in Germany (80%) and France (77%) than Brazil (66%) and the United States (52%), where the prevalence of prescription decreases particularly in patients with CKD stage 5. In the multivariable regression model, RAASi prescription was least common in the United States and more common in patients who were younger, had diabetes, hypertension, or less advanced CKD. In conclusion, RAASi prescription patterns vary by country, and by demographic and clinical characteristics. RAASi appear to be underused, even among patients with strong class-specific recommendations. Although the reasons for this variation could not be fully identified in this cross-sectional observation, our data indicate that the risk of hyperkalemia may contribute to the underuse of this class of agents in moderate to advanced CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.